Last reviewed 2026-04-20 · How we verify

Takhzyro (LANADELUMAB)

Lanadelumab-flyo binds and inhibits plasma kallikrein, reducing bradykinin generation and controlling angioedema in HAE.

At a glance

Mechanism of action

Lanadelumab-flyo is a monoclonal antibody that targets plasma kallikrein, a protein involved in generating bradykinin, a potent vasodilator. By inhibiting plasma kallikrein, the drug reduces the production of bradykinin, thereby preventing the swelling and pain associated with hereditary angioedema (HAE).

Approved indications

• Hereditary angioneurotic edema

Common side effects

• Injection site reactions
• Upper respiratory infection
• Headache
• Rash
• Diarrhea
• Dizziness
• Myalgia
• Hypersensitivity
• Increased aspartate transaminase
• Increased alanine transaminase

Key clinical trials

• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia
• A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
• A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries
• A Survey of Lanadelumab in Participants With Hereditary Angioedema
• A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
• Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease (PHASE2)
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.